SCHEMBL16405709

SCHEMBL16405709

N#CC1CCN(C(=O)CO)CC1

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 5/20 0.39
ALDH1A1 P00352 3/20 0.37
NPC1 O15118 1/20 0.37
JAK1 P23458 3/20 0.36
PREP P48147 1/20 0.33
AKR1C3 P42330 1/20 0.33
KDM4E B2RXH2 1/20 0.33
JAK2 O60674 2/20 0.32
JAK3 P52333 2/20 0.32
TYK2 P29597 1/20 0.32
FAP Q12884 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14655446 0.85 NAMPT (0.47) DPP4ALDH1A1NPC1JAK1KDM4E
SCHEMBL2597648 0.82 ALDH1A1 (0.58) DPP4ALDH1A1NPC1JAK1PREP
SCHEMBL15808560 0.82 CPN1 (0.46) DPP4ALDH1A1NPC1JAK1PREP
SCHEMBL13079257 0.82 ALDH1A1 (0.36) DPP4ALDH1A1NPC1JAK1PREP
SCHEMBL13045920 0.82 EPHX2 (0.47) ALDH1A1NPC1
SCHEMBL4754538 0.82 ALDH1A1 (0.38) DPP4ALDH1A1NPC1AKR1C3KDM4E
SCHEMBL16405710 0.80 ALDH1A1 (0.37) ALDH1A1NPC1AKR1C3
SCHEMBL13282679 0.78 DPP4 (0.49) DPP4ALDH1A1NPC1
SCHEMBL17959731 0.77 ALDH1A1 (0.35) ALDH1A1NPC1AKR1C3
SCHEMBL932224 0.77 KDM4E (0.35) DPP4ALDH1A1KDM4EJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 US claimed
CN-115835908-A Bicyclic heterocycles as FGFR inhibitors 因赛特公司 2023-03-21 CN claimed
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2023-03-21 US claimed
EP-4045151-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-08-24 EP claimed
WO-2021076602-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-04-22 WO claimed
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-04-15 US claimed
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 US disclosed
CN-115835908-A Bicyclic heterocycles as FGFR inhibitors 因赛特公司 2023-03-21 CN disclosed
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2023-03-21 US disclosed
EP-4045151-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-08-24 EP disclosed
WO-2021076602-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-04-22 WO disclosed
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-04-15 US disclosed
US-10426169-B2 Heteroarylpiperidine and -piperazine derivatives as fungicides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2019-10-01 US disclosed
EP-2921494-A1 HETEROARYLPIPERIDINE AND HETEROARYLPIPERAZINE DERIVATIVES Bayer Intellectual Property GmbH (DE) 2015-09-23 EP disclosed
EP-2921492-A1 HETEROARYLPIPERIDINE AND HETEROARYLPIPERAZINE DERIVATIVES Bayer Intellectual Property GmbH (DE) 2015-09-23 EP disclosed
EP-2921493-A1 HETEROARYLPIPERIDINE AND HETEROARYLPIPERAZINE DERIVATIVES Bayer Intellectual Property GmbH (DE) 2015-09-23 EP disclosed
EP-2921485-A1 ISOXAZOLE DERIVATIVES Bayer Intellectual Property GmbH (DE) 2015-09-23 EP disclosed
EP-2921481-A1 4-PIPERIDINE CARBOXYLIC ACID DERIVATIVES Bayer Intellectual Property GmbH (DE) 2015-09-23 EP disclosed
US-20150024935-A1 HETEROARYLPIPERIDINE AND PIPERAZINE DERIVATIVES AS FUNGICIDES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-01-22 US disclosed
US-20150024935-A1 HETEROARYLPIPERIDINE AND PIPERAZINE DERIVATIVES AS FUNGICIDES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 DPP4 2018/4885ALDH1A1 559/4885NPC1 3370/4885
US-10426169-B2 Heteroarylpiperidine and -piperazine derivatives as fungicides RB1, RBX1, RRP12 DPP4 3890/4885ALDH1A1 1534/4885NPC1 3953/4885
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 DPP4 2018/4885ALDH1A1 559/4885NPC1 3370/4885
US-20150024935-A1 HETEROARYLPIPERIDINE AND PIPERAZINE DERIVATIVES AS FUNGICIDES RB1, RBX1, RRP12 DPP4 3697/4885ALDH1A1 1608/4885NPC1 4012/4885
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 DPP4 2018/4885ALDH1A1 559/4885NPC1 3370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.